Study Summary
To assess the safety of administering allogenic, donor-derived CD19/CD22-CAR T cells that meet established release specifications in adults with B-cell ALL following a myeloablative conditioning regimen and Orca-T to determine if this will augment graft versus leukemia without increasing acute GVHD or graft failure.
Want to learn more about this trial?
Request More InfoInterventions
Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)DRUG
CD19/C22CAR T cells will be administered at a dose of CAR+ cells/kg body weight via IV administration
Treg CD34+HSPC (Orca-T)DRUG
Purified donor-derived regulatory T-cell (Treg) plus CD34 + hematopoietic progenitor cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Stanford Cancer Center | Palo Alto | California | United States |